The Bodycote Board approved the payment of an interim dividend for 2026 of 7.2p to those shareholders on the register of Bodycote plc on 1 October 2026 to be paid on 5 November 2026.
Other financial highlights include:
- Core organic revenue growth of 9.6%, in-line with expectations (Group: 3.3% growth, 6.5% organic)
- Strong growth delivered in their target markets of Aerospace & Defence, Industrial Gas Turbines, Medical, Semiconductors; partly offset by continued weakness in Automotive, particularly in Europe
- Growth led by Specialist Technologies, with organic revenue up 16.7%, reflecting favourable end market mix and Aerospace programme exposure. Precision Heat Treatment organic growth of 6.4%
- Core adjusted operating margins +30bps to 16.2%; growth and Optimise benefits partly offset by higher variable pay and growth project ramp-up costs. Group +110bps as Non-Core scale reduces
- Group adjusted operating profit up 10.7% to £61.0m (Core: £60.4m); Statutory operating profit up 10.7% to £45.6m
- Adjusted basic EPS up 18.3% at 25.2p (H1 25: 21.3p), statutory EPS of 18.1p (H1 25: 15.5p)
- Optimise programme on-track with benefits building. Exploring options to expand programme to include additional sites exposed to more challenging Automotive and Industrial regional markets
- FY26 outlook unchanged : expect to deliver organic revenue growth and margin improvement, supported by Optimise benefits and despite higher variable pay and growth investment costs; expect further strategic progress in H2 and remain confident in the delivery of their mid-term targets
